Gastric Cancer

>

Latest News

Zanidatamab BLA Receives FDA Priority Review for HER2+ Biliary Tract Cancer
Zanidatamab BLA Receives FDA Priority Review for HER2+ Biliary Tract Cancer

May 29th 2024

Zanidatamab could become the first FDA-approved, HER2-targeted treatment for HER2-positive biliary tract cancer.

FLOT vs CROSS in Resectable GEJ Adenocarcinoma: Which Regimen is Best?
FLOT vs CROSS in Resectable GEJ Adenocarcinoma: Which Regimen is Best?

April 3rd 2024

PD-L1 Provides Valid Biomarker for Nivolumab/Chemo in Gastric Cancer
PD-L1 Provides Valid Biomarker for Nivolumab/Chemo in Gastric Cancer

February 28th 2024

Optimal Results: Neoadjuvant Durvalumab and Chemotherapy Drive  Improvement in Gastric/GEJ Cancers
Optimal Results: Neoadjuvant Durvalumab and Chemotherapy Drive Improvement in Gastric/GEJ Cancers

January 19th 2024

FDA Issues Complete Response Letter to Zolbetuximab BLA in GI Cancer
FDA Issues Complete Response Letter to Zolbetuximab BLA in GI Cancer

January 9th 2024

Video Series
Video Interviews

More News